ABT
ABBOTT LABORATORIES
NYSE · Healthcare · Medical - Devices · US
$104.57
+1.88%Year over year
Reported trailing growth
- Revenue
- +10.0%
- EBITDA
- -17.7%
- EBIT
- -5.6%
- EPS
- -66.5%
- Free cash flow
- +6.9%
- Operating cash flow
- +4.9%
Forward estimates
Based on analyst estimates
- Revenue
- +9.6%
- EBITDA
- +70.5%
- EPS
- +116.1%
Three-year CAGR
- Revenue
- +0.5%
- EBITDA
- +0.1%
- EBIT
- -1.3%
- Net income
- -2.0%
- EPS
- -1.7%
- Free cash flow
- -1.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026